A six-microRNA signature in plasma was identified as a potential biomarker in diagnosis of esophageal squamous cell carcinoma

Zhou, Xin; Wen, Wei; Zhu, Jun; Huang, Zebo; Zhang, Lan; Zhang, Huo; Qi, Lian Wen; Shan, Xia; Wang, Tongshan; Cheng, Wenfang; Zhu, Dan-Xia; Yin, Yin; Cao, Yan; Zhu, Wei; Shu, Yongqian; Liu, Ping

doi:10.18632/oncotarget.16519

Cited by 59 publications

(46 citation statements)

References 59 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, exosomal miR‐106a‐5p expression was shown to be negatively correlated with patient QMGS, indicating its association with MG clinical typing and severity. Interestingly, one of the dysregulated miRNAs by deep‐sequencing in the present study, miR‐106a‐5p has been previously shown to be associated with the pathogenesis of many cancers, including melanoma, colorectal and gastric cancer, MG, and esophageal squamous‐cell carcinoma . Similarly, miR‐106a‐5p dysregulation has been reported in T‐cells of patients with immune diseases, and may inhibit the proliferation, migration, and invasion of carcinoma cells by modulating various mRNA targets .…”

Section: Discussionsupporting

confidence: 59%

Plasma exosomal miR‐106a‐5p expression in myasthenia gravis

Bao

Liang

et al. 2020

Muscle and Nerve

View full text Add to dashboard Cite

Background Exosomal miRNA expression for myasthenia gravis (MG) has not been studied. Methods Plasma samples from 92 patients with MG and 49 age‐matched healthy controls (HCs) were screened (by means of deep sequencing and quantitative real‐time polymerase chain reaction) for differentially expressed exosomal microRNA (miRNAs). miR‐106a‐5p was chosen to further verify because it is reportedly involved in MG pathogenesis. Spearman's correlation analysis was used to assess correlations between candidate miRNAs and patient quantitative MG scores (QMGSs). Area under the curve (AUC) of the receiver operating characteristic analysis was used to evaluate the diagnostic accuracy of the identified miRNAs for MG. Results miR‐106a‐5p levels were significantly decreased in MG patients compared with HCs, and were associated with patient QMGS. The AUC values for hsa‐miR‐106a‐5p were 0.728 and 0.813 in ocular and generalized MG patients, respectively. Conclusions Exosomal miR‐106a‐5p was expressed differently in different types of MG and was associated with MG severity.

show abstract

Section: Discussionsupporting

confidence: 59%

Plasma exosomal miR‐106a‐5p expression in myasthenia gravis

Bao

Liang

et al. 2020

Muscle and Nerve

View full text Add to dashboard Cite

show abstract

“…In colorectal cancer, miR‐106a was elevated in stool samples from patients with adenomas and colorectal cancer compared to healthy controls (Link et al ., ). In esophageal squamous cell carcinoma, miR‐106a upregulation in plasma was shown to be a diagnostic marker as part of a six‐miRNA signature (Zhou et al ., ). In a study of patients with breast cancer, Wang et al .…”

Section: Discussionmentioning

confidence: 97%

“…controls (Link et al, 2010). In esophageal squamous cell carcinoma, miR-106a upregulation in plasma was shown to be a diagnostic marker as part of a six-miRNA signature (Zhou et al, 2017). In a study of patients with breast cancer, Wang et al found that miR-106a was upregulated in breast tumor specimens and matched sera compared to normal controls .…”

Section: Discussionmentioning

confidence: 99%

miRNA‐106a and prostate cancer radioresistance: a novel role for LITAF in ATM regulation

et al. 2018

View full text Add to dashboard Cite

Recurrence of high‐grade prostate cancer after radiotherapy is a significant clinical problem, resulting in increased morbidity and reduced patient survival. The molecular mechanisms of radiation resistance are being elucidated through the study of microRNA (miR) that negatively regulate gene expression. We performed bioinformatics analyses of The Cancer Genome Atlas (TCGA) dataset to evaluate the association between miR‐106a and its putative target lipopolysaccharide‐induced TNF‐α factor (LITAF) in prostate cancer. We characterized the function of miR‐106a through in vitro and in vivo experiments and employed transcriptomic analysis, western blotting, and 3′UTR luciferase assays to establish LITAF as a bona fide target of miR‐106a. Using our well‐characterized radiation‐resistant cell lines, we identified that miR‐106a was overexpressed in radiation‐resistant cells compared to parental cells. In the TCGA, miR‐106a was significantly elevated in high‐grade human prostate tumors relative to intermediate‐ and low‐grade specimens. An inverse correlation was seen with its target, LITAF. Furthermore, high miR‐106a and low LITAF expression predict for biochemical recurrence at 5 years after radical prostatectomy. miR‐106a overexpression conferred radioresistance by increasing proliferation and reducing senescence, and this was phenocopied by knockdown of LITAF. For the first time, we describe a role for miRNA in upregulating ATM expression. LITAF, not previously attributed to radiation response, mediates this interaction. This route of cancer radioresistance can be overcome using the specific ATM kinase inhibitor, KU‐55933. Our research provides the first report of miR‐106a and LITAF in prostate cancer radiation resistance and high‐grade disease, and presents a viable therapeutic strategy that may ultimately improve patient outcomes.

show abstract

“…What is more, it was revealed that miR‐106a‐5p might act as an anti‐apoptotic factor and could confer the cisplatin resistance of NSCLC cells by targeting ABCA1 . Circulating miR‐106a‐5p has been proved to show high levels in a wide range of other cancers, such as melanoma , colorectal cancer , gastric cancer , as well as esophageal squamous cell carcinoma . MiR‐93‐5p, as a miRNA in the miR‐106b~25 cluster and a paralog of the miR‐17~92 cluster, has been previously verified up‐regulated in NSCLC tissues .…”

Section: Discussionmentioning

confidence: 95%

“…Li et al. confirmed that up‐regulated miR‐93‐5p facilitated tumorigenesis and metastasis of NSCLC by activating oncogenic PI3K/Akt pathway through inhibition of LKB1, PTEN, and p21 expression . Meanwhile, miR‐93‐5p could enhance tumor angiogenesis of NSCLC by suppressing β ‐TRCP2 .…”

Section: Discussionmentioning

confidence: 98%

Identification of four plasma microRNAs as potential biomarkers in the diagnosis of male lung squamous cell carcinoma patients in China

Shan

Zhang

et al. 2018

Cancer Medicine

Self Cite

View full text Add to dashboard Cite

Dysregulated microRNAs (miRNAs) in the plasma of patients with lung squamous cell carcinoma (LSCC) might serve as biomarkers for LSCC diagnosis. The expression of miRNAs was performed using quantitative reverse transcription–polymerase chain reaction (qRT‐PCR) on the basis of Exiqon panels in the initial screening phase including three male LSCC pool samples and one normal control (NC) pool sample (per 10 samples were pooled as one pool sample). After the training (32 LSCC vs. 31 NCs), the testing (55 LSCC vs. 55 NCs), and the external validation (15 LSCC vs. 15 NCs) stages via qRT‐PCR, a four‐miRNA signature (miR‐181a‐5p, miR‐21‐5p, miR‐106a‐5p, and miR‐93‐5p) was identified for LSCC detection. Areas under the receiver operating characteristic (ROC) curve (AUC) of the four‐miRNA panel for the training, the testing, and the external validation phases were 0.795, 0.827, and 0.914, respectively. Then, the four miRNAs were explored in LSCC tissue samples (23 LSCC vs. 23 NCs), and their expression was significantly up‐regulated. However, none of the four miRNAs found significantly up‐regulated in plasma exosomes expect miR‐93‐5p with borderline significance (16 LSCC vs. 16 NCs). In summary, our study established a four‐miRNA peripheral plasma signature, which contributed to diagnosing male LSCC patients in China to a certain degree.

show abstract

A six-microRNA signature in plasma was identified as a potential biomarker in diagnosis of esophageal squamous cell carcinoma

Cited by 59 publications

References 59 publications

Plasma exosomal miR‐106a‐5p expression in myasthenia gravis

Plasma exosomal miR‐106a‐5p expression in myasthenia gravis

miRNA‐106a and prostate cancer radioresistance: a novel role for LITAF in ATM regulation

Identification of four plasma microRNAs as potential biomarkers in the diagnosis of male lung squamous cell carcinoma patients in China

Contact Info

Product

Resources

About